Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. (Q45086471)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Yuki Homma

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Koichi Taniguchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kazuya Nakagawa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Masatoshi Nakazawa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Ryusei Matsuyama

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Ryutaro Mori

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kazuhisa Takeda

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michio Ueda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Yasushi Ichikawa

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kuniya Tanaka

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Itaru Endo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

6 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

Annals of Surgical Oncology

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

670-676

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24310792%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Surgery for pancreatic cancer: recent controversies and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Tumor-associated macrophages: the double-edged sword in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Tregs and rethinking cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y

Importance of CD4(+) T helper cell responses in tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-013-3390-Y